Eric A. Klein - Böcker

Prostate cancer remains the most common malignant tumor in elderly men. The National Cancer Institute estimated 210,000 new cases of prostate cancer in 1997. There is, however, no means of documenting the true incidence of prostate cancer because of the difficulty in detecting all cases. Even using yearly rectal exams, PSA determinations, and ultrasound-guided prostate biopsies, many cases are missed. Suffice it to say that prostate cancer is a widely occurring disease in men and early detection and treatment are extremely important. When I trained in Urology under Dr. Reed Nesbit at the University of Michigan from 1956 to 1959, the diagnosis of prostate cancer was made by a rectal examination and an acid phosphatase determination. If there was a small nodule in the prostate, then an anterior-posterior X-ray of the pelvis was obtained to look for possible bony metastases. If the acid phosphatase was normal and there was no evidence ofa bony metastasis, the prostate was exposed through the perineal approach and a biopsy of the nodule was obtained and sent for frozen section to Pathology to determine if it was indeed a cancer of the prostate. If the biopsy came back positive, the surgeon then proceeded to do a radical perineal prostatectomy. In those days, we usually did eight to ten radical perineal prostatectomies yearly. Many times the nodule that was biopsied was benign, and the incision was simply closed.

More than fifty full-time urological clinicians and surgeons from the internationally acclaimed Cleveland Clinic Glickman Urological Institute describe the most common as well as the most innovative urological procedures from the standpoint of the state-of-the-art, as it is practiced at one of the world's top institutions.

The thoroughly updated and revised third edition of Management of Prostate Cancer provides concise and authoritative guidance to today's best therapeutic regimens for the diagnosis and treatment of prostate cancer.  Highlighting the latest major advances in the field, the book includes chapters on the most controversial areas of prostate cancer – screening, chemoprevention, and active surveillance; updated chapters on genetic risk and progression, biopsy schemes, treatment of complications, and comparative treatment outcomes for surgery; and new chapters on risk factors, new markers, nomograms, and focal therapy. This volume also features overviews of new and emerging drugs and treatment paradigms for castrate resistant disease, advances that promise to extend life and perhaps even cure a subset of men with metastatic disease.With its comprehensive illustrations and contributions from renowned experts in the field, Management of Prostate Cancer, 3rd Edition is an invaluable resource for practitioners in the treatment of prostate cancer.

More than fifty full-time urological clinicians and surgeons from the internationally acclaimed Cleveland Clinic Glickman Urological Institute describe the most common as well as the most innovative urological procedures from the standpoint of the state-of-the-art, as it is practiced at one of the world's top institutions.